AstraZeneca joins Pfizer in MFN pricing deal with US

AstraZeneca joins Pfizer in MFN pricing deal with US

AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.

Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices - Health Journal Online

President Donald Trump secured a major victory Friday as AstraZeneca agreed to lower its prescription drug prices for Medicaid—a move that follows a similar deal made by Pfizer and marks a center point in the administration’s push for more affordable medicine. According to AP, the agreement, made public during a White House Oval Office event, commits AstraZeneca to “most–favored–nation” pricing for Medicaid. That means the company will match the…

Administration reaches deal with AstraZeneca on lowering drug costs

The White House Oct. 10 announced it reached an agreement with AstraZeneca to align drug prices with the lowest paid by other developed nations, also known as the most-favored-nation price. Like the administration’s agreement with Pfizer, AstraZeneca will provide every state Medicaid program in the country access to MFN drug prices on its products and will be required to offer medicines at deep discounts off the list price when selling directly …

Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil – RamaOnHealthcare

Key TakeawaysPharmaceutical companies are shifting towards DTC sales and discounts due to tariff and pricing challenges and President Trump's drug cost

AstraZeneca to offer up to 80% off US drug prices

AstraZeneca joins Trump’s drug pricing plan, pledging $50bn US investment and discounts of up to 80% to cut prescription medicine costs.